Bayer has revealed that its recombinant Factor VIII (rFVIII) replacement therapy Jivi, also known as BAY94-9027, has received approval from the European Commission for the treatment and prophylaxis of bleeding in previously treated haemophilia A patients aged 12 years or older.
As a prophylactic, Bayer recommends that Jivi be used every five days, but notes that it can also we used weekly or twice-weekly.
